natgillin/translations-raw huggingface dataset:
The pharmaceutical composition according to claim 11, wherein said arthritides and connective tissue disease is selected from the group consisting of reactive arthropathies, postinfective arthropathies, inflammatory polyarthropathies, systemic connective tissue disorders, inflammatory spondylopathies, myositis, synovitis, Reiter's disease, seropositive rheumatoid arthritis, rheumatoid arthritis, extraarticular rheumatoid disease, psoriatic and enteropathic arthropathies, juvenile arthritis, arthritis, polyarteritis nodosa and related conditions, necrotizing vasculopathies, dermatopolymyositis, systemic sclerosis, systemic involvement of connective tissue, ankylosing spondylitis and inflammatory spondylopathies. 
Farmaceutski pripravak za uporabu prema zahtjevu 18, gdje su spomenuti artritis i bolest vezivnog tkiva izabrani iz skupine koja se sastoji od reaktivnih artropatija, postinfektivnih artropatija, upalnih poliartropatija, sustavnih bolesti vezivnog tkiva, upalnih spondilopatija, miozitisa, sinovitisa, Reiterove bolesti, seropozitivnog reumatoidnog artritisa, reumatoidnog artritisa, ekstraartikularne reumatske bolesti, psorijatskih 1 enteropatskih artropatija, juvenilnog artritisa, artritisa, poliarteritisa nodoze i srodnih stanja, nekrotizirajućih vaskulopatija, dermatopolimiozitisa, sustavne skleroze, sustavnog zahvaćenja vezivnog tkiva, ankilozantnog spondilitisa i upalnih spondilopatija.
The liquefied gas treatment method according to claim 1, wherein, in the ballast condition, the BOG generated in the cargo tank is supplied as fuel to the sub engine through the compressor line, and the LNG stored in the cargo tank is supplied as fuel to the main engine through the pump line. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se plinovitu komponentu vraćenu u skladišni spremnik (11) ispušta iz skladišnog spremnika zajedno s otparenim plinom nastalim u skladišnom spremniku, te šalje u kompresor (13,13a,13b).
The preparation according to claims 1 to 6, characterised by that said other polysaccharide or polysaccharides are selected from the group comprising free forms or pharmacologically suitable salts of hyaluronic acid, alginic acid, carboxymethyl cellulose, chitosan, oxidised cellulose, fucan, schizophyllan, carboxymethyl-, sulfoethyl- or another water-soluble 1,3-D-glucan or a mixture thereof. 
Pripravak prema zahtjevima 1 do 6, naznačen time da su navedeni drugi polisaharid ili polisaharidi odabrani iz skupine koja sadrži slobodne oblike ili farmakološki pogodne soli hijaluronske kiseline, alginske kiseline, karboksimetil celuloze, kitosan, oksidiranu celulozu, fukan, shizofilan, karboksimetil-, sulfoetil- ili drugi 1,3-D-glukan koji je topiv u vodi ili njihova smjesa.
The chromatographic column was first flushed with 5-6 BV (bed volumes) of acidified water until pH was <4.5. 
Kromatografska kolona je bila isprana s 5-6 BV (bed volumena) zakiseljene vode dok pH nije pao <4.5.
The reaction was started by adding 100 ul of the microsomal suspension to the samples and stopped at selected times by adding 500 ul of methanol. 
Rcakcija je pokrenuta dodavanjem 100 ul suspenzije mikrosoma u uzorke te zaustavljena nakon izabranog vremena dodatkom 500 ul metanola.
or a salt thereof for the treatment or prophylaxis of an infectious disease. Agent according to claim 1, wherein R2 is selected from the group consisting of F, Cl, CF3 and CCl3. 
Sredstvo namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što R2 se bira iz skupine koju čine F, Cl, Br, I, CH2Y, CHY2 i CY3, gdje Y je atom halogena.
A colon cleansing solution comprising: to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and 
Otopina za čišćenje debelog crijeva naznačena time da sadrži: a) 300 do 2000 mmol po litri askorbatnog aniona osiguranog putem askorbinske kiseline, jedne ili više soli askorbinske kiseline, ili njihove smjese; i b) 10 do 200 g po litri polietilen glikola.
R1, R2, R3, and R4 independently represent hydrogen, alkyl, alkoxy, halogen, nitro, cyano, trifluoromethyl, or formyl; 
R!,R', R? i R* neovisno predstavljaju vodik, alkil, alkoksi, halogen, nitro, cijano, trifluorometil ili formil;
In said manner, in particular, also striated, thin, linear looking veneer patterns can be created, which cannot be produced by means of the conventional technique, and which can be termed as "industrial inlays". 
Na taj način se mogu stvoriti naročito iscrtani, tanki furniri koji imaju izgled ravnih crta, koji se ne mogu proizvoditi na takav način kao što je konvencionalna tehnika, i što se može nazvati kao "industrijska umetanja".
the single nucleotide polymorphism marker having an A at the position corresponding to position 87 in SEQ ID NO:3, 
marker polimorfizma jednostrukog nukleotida koji ima A na položaju koji odgovara položaju 87 u SEQ ID NO:3,
drying the reactive composition coated onto the substrate so as to form a basic layer having a permeability such that it may adsorb and release any condensation products formed during step (d) and (e); 
sušenja reaktivne kompozicije premazane na podlozi tako da nastaje osnovni sloj (3) s takvom propusnošću da može adsorbirati i osloboditi bilo kakve proizvode kondenzacije nastale tijekom koraka (d) i (e);
A cell according to claim 9, wherein said E1A and at least one of said E1B coding sequences are separated by at least 10 kb for any copy of said E1A and E1B coding sequences in the genome. 
Stanica prema zahtjevu 9, naznačena time da su navedena E1A i barem jedna od navedenih E1B kodirajućih sekvenci odvojene sa barem 10 kb za bilo koju kopiju navedenih E1A 1 E1B kodirajućih sekvenci u genomu.
These sealing means 17 cooperates with the inwardly facing surface of the lower part of the outer wall 16 of the base unit 3, in order to provide a hermetical sealing as described above for the embodiments as illustrated with FIGS. 
To sredstvo 17 za brtvljenje djeluje zajedno s prema unutra okrenutom površinom donjeg dijela vanjske stijenke 16 osnovne jedinice 3, da se osigura hermetičku zabrtvljenost, kao što je gore opisano za izvedbe prikazane na slikama 2- 5b.
passing the produced hot gases into the pay zone of the oil reservoir wherein said thermal gas emitting composition (TGEC) and said reaction initiator stabilizer (RIS) are separately introduced into said oil reservoir and are contacted in the pay zone of said oil reservoir to initiate a chemical reaction producing heat and gases, and wherein the TGEC is continuously introduced into the oil reservoir and the RIS is introduced simultaneously and in a continuous or intermittent way into the oil reservoir. 
- < aluminija ili aluminijevih legura s magnezijem, u čemu se navedeni sastav koji emitira termalni plin (TGEC) 1 navedeni stabilizator -inicijator reakcije (RIS) odvojeno uvode u navedeno naftno ležište i dovode se u kontakt u zoni iskoristivosti navedenog naftnog ležišta da iniciraju kemijsku reakciju proizvodeći toplinu i plinove, i u čemu se TGEC kontinuirano uvodi u naftno ležište, a RIS se u naftno ležište uvodi istovremeno 1 na kontinuirani ili isprekidani način.
The method according to claim 1, wherein the duration, rotational speed and/or intensity of rotation of said mixing element in said first direction is the same as the duration, rotational speed and/or intensity of rotation of said mixing element in said second direction. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su trajanje, brzina vrtnje i/ili intenzitet vrtnje navedenog elementa za miješanje (60) u navedenom prvom smjeru isti kao trajanje, brzina vrtnje i/ili intenzitet vrtnje navedenog elementa za miješanje (60) u navedenom drugom smjeru.
hetCyc1 is a 6-membered heterocycle having 1-2 ring N atoms and optionally substituted with NH2; 
hetCyc1 je 6-eročlani heterocikl s 1-2 N atoma u prstenu i izborno je supstituiran s NH2;
In one particular embodiment, the subject is treated with the VEGF antagonist when the cancer is non-invasive or early stage and treated with the alpha5beta1 antagonist when the cancer is invasive. In another embodiment, subject being treated with the alpha5beta1 antagonist has elevated alpha5beta1 levels in a diseased tissue compared to tissue from a subject not suffering from the disease. 
Protutijelo antagonista anti-VEGE i/ili protutijelo antagonista anti-alfa5betal, za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen/i time, da je bolest odabrana iz skupine koja se sastoji od tumora, imunološke bolesti, ili pri kojoj pojedinac ima povišene razine alfa5betal u oboljelom tkivu, u usporedbi s tkivom kod pojedinca koji ne pati od bolesti.
is selected from hydrogen, halogen, or is an heterocyclic ring selected from pyrimidin-2-yl, pyridin-2-yl or pyrazin-2-yl, optionally substituted with halogen, C1-C4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl or C1-C4 alkyloxy; is hydrogen or C1-C4 alkyl; the radical 
i R4je neovisno odabran iz skupine koju čine vodik, halogen, C1-C4 alkil, difluormetil, trifluormetil, C1-C4 alkiloksi, NR9R10, gdje su R9 i R10 neovisno vodik ili C1-C4 alkil, ili 2-tiazolidin-1,1-dion; ili dvije R3 skupine ili R3 i R4 skupine uzete zajedno tvore šesteročlani heterociklički prsten koji sadrži dušikov atom;
(0.74 mm) drilled axial hole, and was loaded with 40 mg of a (1:1) mixture of propylene glycol and glycerol. 
Osiguran je sa izbušenim aksijalnim otvorom od 0.74 mm, i napunjen je sa 40 mg (1:1) smjese propilenglikola i glicerola.
Free-standing films were obtained by cutting strips of the coatings and removing them from the metal sheet with a scalpel. 
Slobodno stojeći filmovi dobiveni su rezanjem traka od prevlake i njihovim odvajanjem od metalne ploče pomoću skalpela.
wherein X and m are as defined above. 
Gdje su X i m kao što je definirano gore.
The liquefied gas treatment system according to claim 2, wherein the compressor includes a plurality of compression cylinders. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor (150;13) sadrži više kompresijskih cilindara (14).
A method according to claim 2 comprising the further step determining from the received one or more acknowledgement indications the higher data rate to use when transmitting the payload data. A method according to claim 1 comprising the further steps: 
Postupak prema zahtjevu 2, naznačen time, da obuhvaća dodatni korak: određivanje iz jedne ili više zaprimljenih potvrdnih naznaka, o tome koju od većih podatkovnih brzina treba upotrijebiti, kada se vrši prijenos skupova korisničkih informacija (36).
The lack of k agonism accounts for buprenorphine's freedom from the dysphoric and psychotomrnimetic effects often seen with agonist/antagonist drugs. 
Izostajanje k agonizma odgovorno je za buprenorfinovu izuzetost od disforičnih i psihotomimetičkih učinaka koji se često opažaju kod lijekova koji su miješani agonisti/antagonisti.
Item 5: The method or the mixture according to item 4, wherein the antibodies are derived from mammals, such as human, mice or rats. 
Mješavina prema zahtjevu 7, naznačena time što je antitijelo dobiveno od sisavaca, poželjno čovjeka, miševa 1li štakora.
1 shows the XRPD of the hydrogen sulfate salt of Compound 1; 
Sol hidrogen sulfata od Spoja 1 prema zahtjevu 1 u bezvodnom obliku.
The pharmaceutical composition of claim 11, wherein the therapeutic agent is hydrochlorothiazide. 
Farmaceutski sastav prema zahtjevu 13, naznačen time, da terapeutsko sredstvo je hidroklorotiazid.
each R1, is independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, ORa, or SRa; 
svaki R1, je nezavisno vodik, halogen, cijano, nitro, CF3, OCF3, alkil ili supstituirani alkil, alkenil ili supstituirani alkenil, alkinil ili supstituirani alkinil, cikloalkil ili supstituirani cikloalkil, cikloalkenil ili supstituirani cikloalkenil, heterocikl ili supstituirani heterocikl, aril ili supstituirani aril, ORa, ili SRa;
The transdermal delivery device of claim 1, wherein the microspheres consist of the opioid antagonist dispersed in a polymeric matrix. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 4, naznačen time da je opioid antagonist raspršen u mikrosferama.
p is 1. In a yet another aspect, the present invention provides compounds of formula (I) in free or salt form, wherein 
Također, u drugom obliku predloženi izum osigurava spojeve formule (1) u slobodnom obliku ili u obliku soli, u kojoj formuli
the tyrosine at position 10 of the FG loop (SEQ ID NO: 75) is substituted with the amino acid F or W; or the lysine at position 11 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y. 
tirozin na položaju 10 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine F ili W; ili (xi) - tirozin na položaju 11 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine kojučine A, C,D,E,F,G,H,LK,L,M,N,P, Q,R, S, T, V ili W.
Use according to any one of claims 1 and 4-8 or nanoparticles or nanoparticles' aggregates for use according to anyone of claims 2-8, wherein said ionizing radiations are selected in the group consisting of X-Rays, Y-Rays, electron beams and radioisotope emissions. 
Uporaba prema bilo kojem od zahtjeva 1 1 4, ili nanočestice HfO, ili agregati nanočestica HfO, za uporabu prema bilo kojem od zahtjeva 2, 3 i 4, gdje su spomenuta ionizirajuća zračenja odabrana iz skupine koju čine X-zrake, y-zrake, elektronski snopovi i zračenja radioizotopa.
64 the VH region consists of the amino acid sequence shown in SEQ ID NO. 
(€) VH područje se sastoji od aminokiselinskog slijeda prikazanog u SEQ ID NO.
The method according to claim 15, wherein the cancer is selected from lung cancer, squamous cell carcinoma, liver cancer, kidney cancer, breast cancer, colon cancer, colorectal cancer, and prostate cancer. 
uporabu u liječenju protiv karcinoma, gdje je karcinom izabran iz skupine karcinoma prostate, karcinoma mjehura, karcinoma pluća kao što je nemalični stanični karcinom, karcinom pluća (NSCLC), karcinoma, karcinoma, i karcinoma jetre; ili
The method according to claim 1, wherein the step of providing interior equipment within said cuboid shape comprises installing furniture and/or fixtures in the module. 
Postupak sukladno bilo kojem od prethodnih zahtjeva,, pri čemu korak pribavljanja unutarnje opreme navedenog HR P20160612 T1 kuboidnog oblika obuhvaća instaliranje namještaja 1/ili rasvjetnih tijela u modul.
Due to the problem that in particular donepezil hydrochloride in monohydrate form, e.g. donepezil hydrochloride of form I, can transform into an anhydrous form, the choice of the process and of the excipients is critical to achieve the desired water content of the composition or the desired small difference as to water content of donepezil hydrochloride and excipients which result in a highly stable final product. 
Imajući na umu da donepezil hidroklorid u monohidramom obliku, primjerice donepezil hidroklorid oblika 1, može prijeći u bezvodni oblik, za postizanje željene količine vode u pripravku, odnosno male razlike sadržaja vode donepezil hidroklorida i ekscipijensa što rezultira visokom stabilnosti konačnog produkta, kritičan je odabir postupka pripreme i ckscipijensa.
A: Weight of the tablet in air 
Datum objave europske prijave patenta:
Process according to any of claims 1 to 14, wherein steps a) and/or b) are repeated one or more times in order to maintain the concentration of the one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups and/or the concentration of the solubilised lithium within the respective defined concentration ranges. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 13, pri čemu se koraci a) i/ili b) ponavljaju jedan ili više puta kako bi održali koncentraciju jednog ili više biocida koji otpušta aldehid i/ili biocida s jednom ili više aldehidnih skupina i/ili koncentraciju otopljenog litija unutar odgovarajućih definiranih koncentracijskih raspona.
In addition to hydroxyl substituents, the hydrocarbyl residue may also comprise other substituents such as carbonyl, carboxyl, acyl, amino, acylamino, alkoxy, hydroxyamino, alkoxyamino, thiol, disulfide, ether, ester, alkylthio and amide, groups. 
Dodatno uz hidroksil supstituente, hidrokarbilni ostatak može također sadržavati druge supstituente, kao npr. karbonil, karboksil, acil, amino, acilamino, alkoksi, hidroksiamino, alkoksiamino, tiol, disulfid, eter, ester, alkiltio i amid, skupine.
The process of claim 10, wherein the cell line modified is modified to encode and express D13L under the control of a promoter. 
Postupak prema zahtjevu 10, naznačen time da modificirana stanična linija je modificirana da kodira i eksprimira K1 L pod kontrolom promotora.
A pharmaceutically acceptable ester of a compound of claim 12, 13 or 14, wherein the pharmaceutically acceptable esters are the methyl and ethyl esters of the acids of formula I to be used as prodrugs. 
Farmaceutski prihvatljiv ester, naznačen time, da je od spoja prema zahtjevu 12, 13 ili 14, pri čemu farmaceutski prihvatljivi esteri su metil esteri 1 etil esteri od kiselina formule I, koji se upotrebljavaju kao prolijekovi.
The compound or salt for use according to claim 14 wherein the cancer is selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small-cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer and melanoma. 
Spoj ili sol, namijenjeni upotrebi u skladu s patentnim zahtjevom 14, naznačeni time što se rak bira iz skupine koju čine rak mozga, karcinom bazalnih stanica, rak jednjaka, rak želuca, rak gušterače, rak žučnog sustava, rak prostate, rak dojke, rak malih stanica pluća, rak velikih stanica pluća, limfom B-stanica, multipli mijelom, rak jajnika, rak debelog crijeva, rak jetre, rak bubrega i melanom.
reaction of a compound of formula XXXI, wherein A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, and B is as defined in Claim 1, with a compound of formula XXXII, wherein R1 is H; 
reakciju spoja s formulom XXXI, [image] pri čemu A predstavlja potrebnu supstituiranu piridin-4-il skupinu kako je definirano u zahtjevu 1, i B je kako je definirano u zahtjevu 1, sa spojem s formulom XXXII, [image] pri čemu R1 je H;
The overall telegram generated by microprocessor 6a, 6b is received by respective demultiplexer circuit 12a, 12b, which transmits the various bits in each group to respective outputs OUT1a/b, OUT2a/b, OUT3a/b, OUT4a/b, so that the respective telegram TG1, TG2, TG3, TG4 to be transmitted to the respective beacon is reconstructed at each output OUT1a/b, OUT2a/b, OUT3a/b, OUT4a/b. 
Cjeloviti telegram generiran mikroprocesorom 6a, 6b se prima odnosnim demultipleksnim komunikacijskim krugom 12a, 12b koji prenosi različite bitove u svaku grupu odnosnih izlaza OUT1a/b, OUT2a/b, OUT3a/b, OUT 4a/b, tako da se odnosni telegram TG1, TG2, TG3, TG4 kojeg treba prenijeti prema odnosnoj balizi rekonstruira kod svakog izlaza OUTI1a/b, OUT2a/b, OUT3a/b, OUT4a/b.
The scaffold mimetic of a fusion peptide according to claim 12, wherein component (III) comprises at least four amino acid residues, or comprises preferably at least 10 amino acid residues, or comprises more preferably at least 20 amino acid residues. 
Fuzijski peptid prema patentnom zahtjevu 9, naznačen time da komponenta (Ill) obuhvaća najmanje četiri aminokiselinska ostatka, ili poželjno obuhvaća najmanje 10 aminokiselinskih ostataka, ili još poželjnije obuhvaća najmanje 20 aminokiselinskih ostataka,
Effect of various concentration of Compound 4 in a rat tumor model 
Učinak različitih koncentracija spoja 4 u modelu tumora štakora.
The rim block cage according to one of the preceding claims, characterized in that the containers (3a, 3b, 3c, 3d) are interconnected by means of a non-water-conveying connecting piece (13). 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da su spremnici (3a, 3b, 3c, 3d) međusobno povezani putem veze koja ne provodi vodu (13).
A compound of Formula I: wherein: 
Formula IX čime se dobiva spoj Formule XXVII:
Compound (I) for use in the treatment of a disease in the central nervous system, characterized in that Compound (I) is administered semiweekly or weekly in an instant release formulation (IR-formulation), an extended, controlled or a delayed release formulation for oral administration in a dose corresponding to between 20 mg/week and 50 mg/week, calculated as the free base of Compound (I) 
(I za uporabu u liječenju bolesti centralnog živčanog sustava, naznačeno time što se Spoj (I) primjenjuje dvaput tjedno ili jednom tjedno u formulaciji sa trenutnim ispuštanjem (IR-formulacija), u formulaciji sa produženim, kontroliranim ili odgođenim ispuštanjem, za oralnu primjenu u dozi koja odgovara između 20 mg/tjedan 1 50 mg/tjedan, računato kao slobodna baza Spoja (1).
In a preferred embodiment, the above method also comprises a determination of the presence or amount of the anti-TNFalpha therapeutic antibody and Anti-Drug Antibodies to obtain a patient profile, wherein the patient profile indicates the responsiveness to said treatment. 
Metoda iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu se određuje prisutnost ili količina TNFalfa, navedena prisutnost ili količina ukazuje na odgovor pacijenta na liječenje.
or a boronic acid anhydride thereof; the process comprises the steps: 
[image] ili njegovog anhidrida organoborne kiseline, koji sadrži korake: spajanja spojaformule (XVIII):
The mature type I elastase is preferably a human type I elastase. 
(b) kada podliježe autoaktivacijskim uvjetima, proizveden je zreli tip I elastaze.
The antibody or fragment thereof for use according to any of claims 1-9, wherein the antibody or fragment thereof comprises the CDR1, CDR2 and CDR3 domains, as delineated using the Kabat system, in a heavy chain variable region comprising consecutively linked amino acids, the sequence of which is set forth in SEQ ID NO: 25, and the CDR1, CDR2 and CDR3 domains, as delineated using the Kabat system, in a light chain variable region comprising consecutively linked amino acids, the sequence of which is set forth in SEQ ID NO: 29. 
Antitijelo ili njegov fragment za primjenu prema bilo kojem od patentnih zahtjeva 1-9, gdje antitijelo ili njegov fragment sadrži CDRI, CDR2 i CDR3 domene, kao što je obilježeno korištenjem Kabatovog sistema, u varijabilnoj regiji teškog lanca koja sadrži uzastopno vezane aminokiseline, čija je sekvenca prikazana u SEK ID BR: 25, i CDRI, CDR2 i CDR3 domene, kao što je obilježeno korištenjem Kabatovog sistema, u varijabilnoj regiji lakog lanca koji sadrži uzastopno vezane aminokiseline, čija je sekvenca prikazana u SEK ID BR: 29.